Ep 99: The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

BrainStorm wants to hear from you! Send us a text.Ep 99: The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s PlatformIn part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials. Dwyer shares how the field is shifting toward earlier intervention and leveraging artificial intelligence to improve trial efficiency and accuracy. AI can help identify subtle disease patterns and ensure trials enroll appropriate candidates. GAP is also pioneering remote, decentralized trials that bring research into patients' homes rather than requiring frequent clinic visits, aiming to dramatically scale up participation.Dwyer also highlights proven lifestyle interventions that support cognitive health alongside pharmaceutical treatments and suggests multiple treatment approaches may soon be available.This episode of BrainStorm is sponsored by Johnson & JohnsonSupport the show